LifeSignals Receives EU MDR Certification for UbiqVue™ 2A Multiparameter System

Cloud-Based System, Featuring Wearable Biosensor with Chest-Based SpO₂, Enables Active Patient Monitoring Across Hospital and Out-of-hospital Care Settings

MILPITAS, Calif., Dec. 5, 2024 /PRNewswire/ -- LifeSignals, Inc. today announced that the UbiqVue 2A Multiparameter System has received EU MDR Certification, marking another significant milestone in deploying continuous wireless patient monitoring for population health management following FDA 510(k) Clearance last month. UbiqVue 2A is thus approved and CE-marked in accordance with EU regulation on medical devices, which ensures the safety and performance of medical equipment. This is especially significant because the UbiqVue 2A Multiparameter System is designed to be deployed in home, as well as hospital settings to continuously monitor patients' physiological data, replacing laborious and potentially inaccurate spot-checks.

Central to the system is the UbiqVue 2A Biosensor, a single-use, all-in-one wearable device that enables SpO₂** to be continuously collected from the chest, alongside other biodata, for generating a total of twelve monitored parameters, including 2-channel ECG, pulse rate, PPG, respiration rate, body temperature, and motion. The encrypted data is securely transmitted, in near real-time, from the Biosensor via a relay app or an access point to a secure cloud-based system, where it is further signal-processed. Healthcare professionals and care providers can access continuous vital signs, via the UbiqVue web portal, and receive alert notifications.

"This Class IIb EU MDR Certification, typically given to devices intended for the continuous surveillance of vital physiological parameters in anesthesia, intensive care or emergency care, confirms our commitment to deliver bedside patient monitor-equivalent functionality through an affordable, single-use Biosensor," said Surendar Magar, Co-founder and CEO. "By securing the necessary regulatory approvals in various geographies and creating global partnerships with OEMs, service providers, and distributors, we aim to transform healthcare at scale."

The UbiqVue System is expected to play a vital role in advancing both individual patient care and broader population health strategies, reinforcing LifeSignals' mission to deliver innovative, wireless solutions for healthcare systems worldwide. Learn more by visiting: https://www.lifesignals.com/ubiqvue-multiparameter/ 

** White light spectral SpO₂ patented technology licensed from BioIntelliSense, Inc. LifeSignals, Inc. in partnership with BioIntelliSense, carried out the product-level design and processing technology enhancements enabling reliable, continuous SpO₂ monitoring and accurate performance across all skin tones in a chest-worn Biosensor.

About LifeSignals Inc.

LifeSignals delivers scalable patient monitoring solutions for population health. Our UbiqVue Wireless Patient Monitoring System features single-use, multiparameter wearable Biosensors fully driven by proprietary system-on-chip silicon technology. This ready-to-deploy solution ensures seamless, accurate, and economical patient monitoring across clinical and community settings. Learn more at www.lifesignals.com.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

LifeSignals Receives EU MDR Certification for UbiqVue™ 2A Multiparameter System

Sky Labs Inc., BrainU Co., Ltd., and ANDOPEN Co., Ltd. will be recognized as Innovation Award Winners

SEOUL, South Korea, Dec. 27, 2024 /PRNewswire/ -- Following its successful participation last year, Seongnam City will participate in CES 2025, the world's largest consumer electronics and information technology exhibition. The event will take place from January 7 to 10, 2025, in Las Vegas, USA. Seongnam City will operate the "Seongnam Pavilion," which will support 25 local startups from the Seongnam region and highlight their innovative technologies and products. CES 2025 will attract approximately 4,400 companies and over 130,000 attendees worldwide.

At CES 2024, Seongnam City garnered significant attention from domestic and international investors and buyers by showcasing startups with outstanding technological capabilities. This effort established valuable global networks and expanded market opportunities, achieving a total contract value of KRW 145.5 billion. These tangible outcomes highlighted the high level of satisfaction among participating companies.

This year, Seongnam City, a leading innovative hub in South Korea, aims to actively support local startups in expanding into overseas markets and building global networks through its participation in CES 2025. The Seongnam Pavilion will feature cutting-edge technologies and products across advanced industries such as artificial intelligence (AI), healthcare, smart cities, and mobility. Through these efforts, Seongnam City seeks to further solidify its position as a "Global Innovation City."

Notably, three companies from Seongnam were honored with CES Innovation Awards, demonstrating their technological excellence and global competitiveness on the world stage:

Seongnam City stated, "By participating in CES 2025, we aim to showcase Seongnam's innovative technologies to the global stage and provide a launchpad for our startups to expand into international markets."

Meanwhile, the Seongnam Pavilion will feature 25 companies, including BRYTN Co., Ltd., NTL HEALTHCARE Co., Ltd., EMTAKE Inc., AWESOME LAB Co., Ltd., JNL Co. Ltd., Linkface Co., Ltd., Emma Healthcare Co.,Ltd., NC& Co.,Ltd, Becon Co.,Ltd, LITBIG, Inc., GeodeSound., Inc, MEDIAIPLUS, INC, BoS Semiconductors, Sky Labs Inc., STRATIO, INC., BrainU Co., Ltd., analogue plus Co.,Ltd., EX Healthcare Inc., Mangoslab, Littleone, Bluefeel Co., Ltd., Aram Huvis Co., Ltd., Real Design Tech Co.,Ltd., Crescom Co., Ltd., ANDOPEN Co., Ltd. These companies are set to unveil their groundbreaking technologies at the exhibition.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Seongnam City to Participate in CES 2025, Paving the Way as a Global Innovation Hub